ArticleScience advances2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
23.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 55 citations in OpenAlex.
- Review
- 70 Years of DON and Beyond: Glutaminase Inhibition as a Synergistic Strategy in Cancer Combination Therapy.Pharmaceutics · 2026Review
- LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.Cancer discovery · 2026Article
- Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma.Journal of cellular physiology · 2026Review
- Overview of glutamine metabolism in stromal components of the tumor microenvironment and potential anti-tumor therapies.Genes & diseases · 2026Review
- Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer.The EMBO journal · 2026Article
- Targeting glutamine metabolism to modulate macrophage functions in the tumor microenvironment.Discover oncology · 2026Review
- Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Drowning in cysteine.Nature metabolism · 2026Article
- Article
- Tumor-intrinsic metabolic pathways essential for tumorigenesis and resistance to anti-PD1 in oncogenic Kras-driven lung adenocarcinoma.Cancer & metabolism · 2026Article
- Review
- Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade.Journal of translational medicine · 2026Article
- Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer.Oncology research · 2026Review
- Targeting FSP1 triggers ferroptosis in lung cancer.Nature · 2026Article
- Immune and metabolic remodeling following bariatric surgery: Implications for targeted immunotherapy (Review).International journal of molecular medicine · 2026Review
- Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition.Frontiers in cell and developmental biology · 2026Review
- Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Review
- NRF2-SOX4 complex regulates PSPH in hepatocellular carcinoma and modulates M2 macrophage differentiation.Cancer gene therapy · 2025Article
- Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
Corrections and comments
- Update of
Authors and funding
28 authors at 9 institutions in 2 countries.
Ray PillaiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-8335-3463
Sarah E LeBoeufDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Yuan HaoApplied Bioinformatics Laboratories, New York University Langone Health, New York, NY 10016, USA.ORCID 0000-0002-4031-7868
Connie NewDepartments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-8469-9725
Jenna L E BlumLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA.
Ali RashidfarrokhiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Shih Ming HuangDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-5070-1732
Christian BahamonDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0003-2271-8083
Warren L WuDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Burcu Karadal-FerrenaDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-2066-3173
Alberto HerreraDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0003-4189-9051
Ellie IvanovaDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-1850-9505
Michael CrossDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-2446-9167
Jozef P BossowskiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.
Hongyu DingDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-7531-4771
Makiko HayashiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-9189-0058
Sahith RajalingamDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0003-3669-3729
Triantafyllia KarakousiDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-1950-7341
Volkan I SayinInstitute of Clinical Sciences, Department of Surgery, Sahlgrenska Center for Cancer Research, University of Gothenburg, 41345 Gothenburg, Sweden.ORCID 0000-0002-5225-8260
Kamal M KhannaLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.ORCID 0000-0002-9328-3817
Kwok-Kin WongLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.ORCID 0000-0001-6323-235X
Robert WildDracen Pharmaceuticals Inc., San Diego, CA 92121, USA.
Aristotelis TsirigosLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.ORCID 0000-0002-7512-8477
John T PoirierLaura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA.ORCID 0000-0001-9795-5644
Charles M RudinDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10655, USA.ORCID 0000-0001-5204-3465
Shawn M DavidsonLewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ 08544, USA.ORCID 0000-0002-3475-0382
Sergei B KoralovDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-4843-3791
Thales PapagiannakopoulosDepartment of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-2251-1624
New York University · USNYU Langone Health · USMassachusetts Institute of Technology · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USRutgers, The State University of New Jersey · USSahlgrenska University Hospital · SETracon Pharmaceuticals (United States) · USVA NY Harbor Healthcare System · US
Funding
The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4MTumor Immunology (TIM) Research ProgramP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 1985 to 2025
$21.1MTRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 1985 to 2005
$3.9MTraining Program in Immunology and InflammationT32AI100853 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 to 2025
$790kRole of S.aureus in Cutaneous T Cell Lymphoma PathogenesisR01CA271245 · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2025 to 2025
$545kNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA227649NCI NIH HHS R01 CA271245NCI NIH HHS R37 CA222504NCI NIH HHS T32 CA009161NHLBI NIH HHS R01 HL125816NIAID NIH HHS T32 AI100853NIH HHS S10 OD021747
Abstract
Loss-of-function mutations in
Indexed as
Lung NeoplasmsEnzyme InhibitorsGlutamineHumansKelch-Like ECH-Associated Protein 1MutationNF-E2-Related Factor 2Enzyme InhibitorsGlutamineKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.